Evidence map›Paper›PMID 39836012›Full record

Trial reportClinical and translational gastroenterology2025

A Randomized, Comparative Trial of a Potassium-Competitive Acid Blocker (X842) and Lansoprazole for the Treatment of Patients With Erosive Esophagitis.

Siying Zhu, Muzhou Han, Ye Zong, Fandong Meng, Qi Liu, Biguang Tuo, Zhenyu Zhang, Qizhi Wang, Xiaowei Liu, Song He and 14 more

Abstract readRandomized Controlled TrialComparative StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Siying ZhuDepartment of Gastroenterology, National Clinical Research Center for Digestive Diseases, Beijing Digestive Disease Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Muzhou HanDepartment of Gastroenterology, National Clinical Research Center for Digestive Diseases, Beijing Digestive Disease Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Ye ZongDepartment of Gastroenterology, National Clinical Research Center for Digestive Diseases, Beijing Digestive Disease Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Fandong MengDepartment of Gastroenterology, National Clinical Research Center for Digestive Diseases, Beijing Digestive Disease Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Qi LiuDepartment of Gastroenterology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Biguang TuoDepartment of Gastroenterology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Zhenyu ZhangDepartment of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Qizhi WangDepartment of Gastroenterology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Xiaowei LiuDepartment of Gastroenterology, Xiangya Hospital, Central South University, Changsha, China.
Song HeDepartment of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yanbo ZhenDepartment of Gastroenterology, Jinan Central Hospital, Jinan, China.
Dong ShaoDepartment of Gastroenterology, The First People's Hospital of Changzhou, Changzhou, China.
Shenglan WangDepartment of Gastroenterology, Digestive Disease Institute, Tongji Hospital, Tongi, University School of Medicine, Shanghai, China.
Baohong XuDepartment of Gastroenterology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Xing LiDepartment of Gastroenterology, Affiliated PingXiang Hospital, Southern Medical University, Pingxiang, China.
Haitao TangDepartment of Gastroenterology, Liuan People's Hospital, Liuan, China.
Yangde MiuDepartment of Gastroenterology, Taizhou Municipal Hospital, Taizhou, China.
Chengxia LiuDepartment of Gastroenterology and Hepatology, Binzhou Medical University Hospital, Binzhou, China.
Jiuye HuDepartment of Gastroenterology, Affiliated Hospital of Xiangnan University, Chenzhou, China.
Pingsheng HuJiangsu Sinorda Biomedicine Co., Ltd., Taicang, China .
Jin XiuJiangsu Sinorda Biomedicine Co., Ltd., Taicang, China .
Ming LuJiangsu Sinorda Biomedicine Co., Ltd., Taicang, China .
Yongdong WuDepartment of Gastroenterology, National Clinical Research Center for Digestive Diseases, Beijing Digestive Disease Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.ORCID 0009-0006-4438-3527
Shutian ZhangDepartment of Gastroenterology, National Clinical Research Center for Digestive Diseases, Beijing Digestive Disease Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

Funding

National Natural Science Foundation of China 81600432
6 · The paper itself

Abstract

introductionX842 is a new type of gastric acid-suppressing agent with a rapid onset of action and a long duration of effect. We aim to investigate the efficacy and safety of different doses of X842 vs lansoprazole in the treatment of patients with erosive esophagitis (EE).

methodsThis phase 2 study included 90 patients with EE (Los Angeles grades A-D) who were randomized (1:1:1) to receive oral low-dose X842 (50 mg/d, n = 31), high-dose X842 (100 mg/d, n = 31), or lansoprazole (30 mg/d, n = 30) for 4 weeks. The main efficacy end point was the EE healing rate, which was the proportion of patients who achieved endoscopic healing after 4 weeks of treatment.

resultsFor intention-to-treat analysis, the EE healing rates at 4 weeks were 93.6% (29/31), 79.3% (23/29), and 80.0% (24/30) for the X842 50 mg, the X842 100 mg, and the lansoprazole 30 mg groups. For per-protocol analysis, the EE healing rates at 4 weeks were 93.6% (29/31), 80.8% (21/26), and 82.1% (23/28) in the 3 groups, respectively. The EE healing rate did not significantly differ among the 3 groups in either the intention-to-treat ( P = 0.2351) or per-protocol ( P = 0.3320) analysis. The incidence of drug-related treatment-emergent adverse events did not differ among groups. No severe drug-related treatment-emergent adverse events occurred in the X842 group. DISCUSSION: Our findings confirmed that X842 had efficacy and a favorable safety profile similar to those of lansoprazole. Therefore, X842, a novel potassium-competitive acid blocker, is expected to become a promising therapeutic agent for EE.

Indexed as

Esophagitis, PepticLansoprazoleProton Pump InhibitorsAdministration, OralAdultAgedDose-Response Relationship, DrugEsophagoscopyFemaleHumansIntention to Treat AnalysisMaleMiddle AgedPyrrolesSulfonamidesTreatment Outcome1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineLansoprazoleProton Pump InhibitorsPyrrolesSulfonamideserosive esophagitislansoprazolepotassium-competitive acid blockerX842

Identifiers

PMID39836012
PMCPMC12020686

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.